Infigratinib (brand name: Tukysa) is a prescription drug used to treat adults diagnosed with advanced or metastatic non-small cell lung cancer (NSCLC) with a specific genetic marker known as EGFR exon 20 insertion mutations. It is a type of targeted therapy, meaning it works by targeting specific molecules involved in cancer cell growth. Infigratinib is taken orally as a capsule and is used in combination with other treatments such as chemotherapy. It works by blocking proteins called epidermal growth factor receptors (EGFRs), which are found on the surface of cancer cells and help them grow and spread. By blocking these proteins, the drug can help stop the growth of the tumor.
Infigratinib, sold under the brand name Truseltiq, is a medication used to treat a specific type of bile duct cancer. Here's a breakdown of its key aspects:
Purpose:
- Targets a particular type of bile duct cancer (cholangiocarcinoma) with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement. This means the cancer cells have an abnormality in a specific gene that fuels their growth.
- Infigratinib is only prescribed after other treatment options have been explored and proven ineffective.
Mechanism of Action:
- Classified as a kinase inhibitor. Kinases are enzymes that play a crucial role in cell signaling pathways. Infigratinib specifically blocks FGFR, thereby interrupting the signals that instruct cancer cells to multiply and grow.
Administration:
- Taken orally, typically as capsules.
Important Safety Information:
- Infigratinib is not suitable for everyone and has potential side effects, including:
- Increased levels of certain minerals in the blood.
- Nail and mouth issues.
- Fatigue, hair loss, and dry skin.
- Digestive problems like diarrhea, nausea, and vomiting.
Disclaimer:
- Infigratinib is a prescription medication and should only be used under the guidance and supervision of a licensed medical professional.
- The information provided here is for educational purposes only and does not constitute medical advice.
Additional Resources:
- You can find more details about Infigratinib on the websites of reputable health organizations like the National Cancer Institute (https://www.cancer.gov/) or the American Cancer Society (https://www.cancer.org/).